Orforglipron, like all GLP-1 therapies, works best when conceptualized as a long-term or indefinite treatment rather than a temporary intervention, similar to how blood pressure medications manage hypertension without "curing" it
And they can only pick one side: Lower unit prices and volume goes up, or lower volume and unit prices go up
Serious but less common risks include pancreatitis, gallbladder problems, dehydration from severe vomiting or diarrhoea, worsening diabetic eye disease in some patients with rapid glucose improvement, and allergic reactions
Accelerate Recovery
82 The direct impact of GLP-1RAs on significant renal outcomes remains uncertain
Research Applications Melanocortin-Receptor Research MT-1 is studied as an agonist at the melanocortin-1 receptor (MC1R), a GPCR central to pigment-cell signalling